Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod in pT3-4 cN0M0 Melanoma
NCT04126876Phase 2Recruiting
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of tilsotolimod in Malignant Melanoma (MM). Started Jan 2020; status: recruiting.
02
Drugs
tilsotolimod
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04126876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126876.